Source: International Congress 2018 – Fungal infection in the intensive care unit



Rating:

Share or cite this content

Citations should be made in the following way:
M. Leone (Marseille, France). Choosing the right antifungal agent. International Congress 2018 – Fungal infection in the intensive care unit

Member's Comments

No comment yet.

Related content which might interest you: Do we have any alternative therapeutic option beyond antibiotics? Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Combination is better than a single agent to create pleurodesis in rabbits Source: Eur Respir J 2005; 26: Suppl. 49, 446s Year: 2005 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 The evidence regarding early antifungal treatment Source: International Congress 2018 – Fungal infection in the intensive care unit Year: 2018 Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Direct - acting oral anticoagulants: which agent for which patient? Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress Year: 2019 Drug resistant pattern of antitubercular drugs in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012 Macrolides as anti-inflammatory agents in CAP Source: Eur Respir Monogr 2014; 63: 243-255 Year: 2014 Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agent Source: Annual Congress 2010 - Models of airways disease Year: 2010